Orforglipron is an oral drug from Eli Lilly that’s in trial stage. The New York Times reports that in a trial of over 500 ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

As the newly appointed federal vaccine advisory panel prepares to reevaluate childhood vaccination schedules, Gov. Josh ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Eli Lilly & Co. is bouncing back after a turbulent period, riding out volatility and posting a strong revenue increase in Q1 ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

In its first-quarter 2025 investor letter, Macquarie Large Cap Growth Fund highlighted stocks such as Eli Lilly and Company ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...